Martinsried, Munich, August 22, 2007 / b3c newswire / - Proteros biostructures GmbH, located in Martinsried, announced that the BayBG Bayerische Beteiligungsgesellschaft mbH in Munich has again invested, currently €1,000,000, in Proteros as a silent partner. The additional equity capital permitted the acquisition of an additional €4,200,000 in financing and research funds. The specialist for three-dimensional protein structure analysis will use the capital in particular for increasing service capacity and expanding the fragment screening and protein production areas.
Proteros is Europe's largest company focused on supporting structure-based lead optimization by X-ray protein structure analysis. The analysis of protein and protein-ligand structures for international pharmaceutical, biotechnology and crop protection companies facilitates more rapid and cost-efficient development of drugs for medicinal products.
"Proteros possesses technological unique selling propositions that are advancements based on the more than 30 years of research by chemistry Nobel Prize laureate Prof. Robert Huber of the Max-Planck Institute for Biochemistry," comments BayBG managing director Peter Pauli while describing the nature of Proteros products and services. Pauli justified the renewed commitment of BayBG with the sustained positive development of the company since its founding in 1998 and the continuously growing industry demand for protein structure analyses by Proteros.
"Ever since the beginning, the decision makers at BayBG have positively assessed the potential of our company," says Proteros CEO, Dr. Torsten Neuefeind. "Moreover, I value the long-term investment horizon of the BayBG that allows us to further effectively develop the service-based business of Proteros."
Proteros biostructures GmbH - www.proteros.com
Proteros biostructures is a privately held company that offers services and products for X-ray structure analysis and the production of proteins. Proteros accelerates and optimizes structure analysis and structure-based drug discovery through its expertise and unique technologies, such as the Free Mounting SystemTM (FMSTM) and the PicodropperTM. Proteros' collection of Gallery Structures, a catalogue of established drug targets, provides the means to generate protein-ligand structures within a few weeks, realizing a significant time and cost advantage for its clients.
BayBG - www.baybg.de
Through its investments, BayBG is currently strengthening the capital base of 550 Bavarian medium-sized companies. The BayBG is thus the Bavarian market leader among medium-sized enterprise-oriented investment companies. Through its commitment, the BayBG enables the companies to realize expansion and innovation plans, make corporate succession plans as well as optimize the capital structure and implement of turn-around measures.
Proteros biostructures GmbH
Dr. Hajo Schiewe, Ph.D.
Executive VP Business Development